Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 85INDUSTRY 16NETWORK 5NIH 4OTHER_GOV 3UNKNOWN 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Uterine Cervical Neoplasms 6Esophageal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Nasopharyngeal Carcinoma 5Lung Neoplasms 5Nasopharyngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Breast Neoplasms 3Neoplasms, Germ Cell and Embryonal 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Squamous Cell 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Oesophagogastric Cancer 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Locally Advanced Cervical Cancer 1Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer 1Gastro-enteropancreatic neuroendocrine tumor 1Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1Endometrial Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Carcinoma, Ovarian Epithelial 1

Interventions

Cisplatin 3sintilimab 2toripalimab 1camrelizumab 1anlotinib 1TP protocol 1Radiotherapy 1Radiation 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Immune Checkpoint Inhibitors 1Fluorouracil 1Docetaxel 1Chemoradiotherapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Esophageal Squamous Cell Carcinoma × Cisplatin × Clear all
NCT03914443 2025-05-31

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

National Cancer Center, Japan

Phase 1 Completed
37 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05007145 2021-12-21

REVO

Fujian Cancer Hospital

Phase 2 Unknown
92 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04063683 2021-08-24

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).

Henan Cancer Hospital

Phase 2 Unknown
47 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡